Feeds:
Posts
Comments

Archive for the ‘Roche’ Category

 

TODAY’S NEWS

Roche: Our upcoming diabetes drug works better than Byetta. Will be interesting to see the full set of data.

AstraZeneca’s experimental oncology drug Zactima: let’s step back for a time-out.

Genta: time to give up on Genasense? Not sure this horse is ever going to gallop.

RECOMMENDED

Compliance Training. Impactiviti’s partner network includes solutions providers for every level of compliance training – from sales reps to home office employees. Ethics, Regulatory compliance, Diversity – you name it. Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.

PLUS

This week, I attended a very enjoyable ePatient Connection conference (put on by Kevin Kruse). It was excellent: here’s a review.

JUST FOR FUN

Curious about all that wine flavor jargon? Check out this neat little visualization!
—–——–
Coming up next week:

eComm

Nov. 3-4 – eyeforpharma’s 4th Annual eCommunication and On-line Marketing Summit, Philadelphia, PA. I’ll be part of a panel on social networking, and live-blogging/Twittering. Here’s a discount code to save $400 off your registration: SPEAK

———-

Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)

Connect with Steve Woodruff

Read Full Post »

Tune in TODAY – I’ll be doing a live on-line interview on Social Media in Pharma with Paul Chaney – starts at 1 pm EST (just use the call-in number – see the link). Also, here’s a page on my site with all sorts of social media resources for pharma professionals: http://bit.ly/socialrx

TODAY’S NEWS

AstraZeneca’s new Plavix-competitor Brilinta expected to go big – It is the first antiplatelet drug to demonstrate it can reduce cardiovascular (CV) deaths compared to the current gold standard treatment, Plavix (clopidogrel) in patients with acute coronary syndromes (ACS). Results of the 18600 patient Phase III PLATO trial comparing the two drugs, were revealed at the recent European Society of Cardiology (ESC) Congress in Barcelona…Platelet expert Dr Victor Serebruany agreed the mortality data is ”marvelous,” with 107 extra lives saved compared to Plavix. “It has never been seen before and no one expected it,” he saidmore

Big oncology news (approval for new lymphoma drug) today – Allos Therapeutics Inc. said Friday that regulators approved its injectable drug Folotyn as a treatment for peripheral T-cell lymphoma, a group of rare, agressive blood cancers, sending its shares soaring. Allos said the Food and Drug Administration granted accelerated approval, allowing the company to market Folotyn for use in patients whose cancer has returned or not responded to previous treatment. Allos expects to begin selling the drug in October. There are no drugs on the market that treat peripheral T-cell lymphoma, Allos saidmore Plus, some future hope from Roche on melanoma?

So the FDA is finally going to start wresting with social media in pharma! Here’s what companies need to do to prepare for the hearing this fall. And here also.

This bothers me.

RECOMMENDED

Compliance training. When y0u need compliance training development partners for your employees, we’ve got g. Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for information and recommendations!

PLUS

An interview with the President and CEO of Sanofi-Aventis US (Gregory Irace), on the big changes they are undergoing to re-structure the company, and the way they deliver information.

Coming up next month:

DigitalPharma

Oct. 19-21 – eXL’s Digital Pharma conference, Bridgewater, NJ. This event will be quite progressive, with more of an informal “unconference” format to maximize interaction. I’ll be co-leading a pre-conference workshop on the 19th on social media, and live-blogging/Twittering. Here’s a discount code for 15% your registration: P615WOO

———-

Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)

Connect with Steve Woodruff

Read Full Post »

TODAY’S NEWS

Osteoporosis. The status of new treatments from Wyeth, Pfizer, and Amgen.

FDA approves H1N1 vaccines – The Food and Drug Administration on Tuesday approved vaccines designed to protect against the H1N1 influenza virus, a key step before starting a vaccination campaign. The approval was announced by Health and Human Services Secretary Kathleen Sebelius at a hearing that was held by the House Energy and Commerce Committee. An FDA spokeswoman said the agency approved vaccines made by a unit of Sanofi-Aventis SA, Novartis AG, CSL Ltd. and AstraZeneca PLC’s MedImmune unitmore

Roche‘s anemia drug Mircera – not coming to a pharmacy near you.

Pfizer math.”

Interesting. Less than 1% of doctors see bias in on-line CME? What do you think?

Social Media Monitoring – should pharma bother? Only if you plan to act on it…

RECOMMENDED

Gaming and Simulations. Training and marketing don’t have to be boring. The Impactiviti Partner network has great technology vendor/partners who develop games and simulations. Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for information and recommendations!

PLUS

Ben & Jerry’s. I visited their HQ in Vermont for a tour last week – a very impressive marketing approach. Here are my impressions.

JUST FOR FUN

Not just for wussy little boys. Less than a minute will get you a good chuckle!

———-

Subscribe to the Impactiviti blog via e-mail

Connect with Steve Woodruff

Read Full Post »

FDA to Watson on 24-week Trelstar: Ummm, not yet. Oh, and to Bayer and J&J for Xarelto: Ummmm, not yet.

Bayer’s Yaz and blood clots – the legal wrangling continues.

Solvay selling out on pharma, narrows it down to 2 bidders – Solvay has whittled down the list of bidders for its pharmaceuticals business to Nycomed, the privately held Swiss company, and Abbott Laboratories of the US…more

Transplant drugs have to alter labels to include increased risks – The U.S. Food and Drug Administration today said that it will require manufacturers of some immunosuppressant drugs used in kidney (renal) transplantation to update their labeling to reflect an increased risk of infections…more

More bad news on hormone therapy – Women who took hormone replacement therapy after menopause had a sharply increased risk of ovarian cancer, researchers in Denmark are reporting…more

It’s very early, but this Roche potential cancer drug shows some interesting promise. Glioblastoma is a real problem, in need of some new therapies. And, speaking of early, here’s a very counter-intuitive positive result for an Alzheimer’s treatment. Like, 180-degrees counter-intuitive!

PLUS: From Forrester Research – How to Create a Social Application for Life Sciences without Getting Fired ($$ report).

AND: What are the pharma company early adopters doing on Twitter? Here’s the overview, with stats.

———-

Subscribe to the Impactiviti blog via e-mail

Subscribe to the Impactiviti blog via RSS

Connect with Steve Woodruff

Read Full Post »

Roche-Genentech – the cuts begin – Anxiety rippled through Genentech this week as the Swiss drug firm Roche began to cut rank-and-file jobs as it folds the South San Francisco biotech firm into its global operations…more

Sciele-Victory link-up: Nah, guess not.

J&J, Vertex, and biodollars.

Merck gets expanded approval for HIV drug – The Food and Drug Administration said Thursday it has approved expanded use of a Merck & Co. HIV drug, Isentress. Known chemically as raltegravir, it is now approved for treating new and existing patients with the virus that causes AIDS, in combination with other types of HIV drugs…more

Wyeth has the anti-aging market to itself, and didn’t know it!

———-

Subscribe to the Impactiviti blog via e-mail

Subscribe to the Impactiviti blog via RSS

Connect with Steve Woodruff

Read Full Post »

Ouch. Jury returns $ 1.67 billion verdict against Abbott (patent infringement vs J&J) – A U.S. federal jury returned a $1.67 billion verdict against Abbott Laboratories in a patent suit brought by Johnson & Johnson related to arthritis treatments, the drug companies said on Monday. An Abbott spokesman said the company would appeal the verdict delivered in Marshall, Texas. The case involves Humira, Abbott’s newer blockbuster drug that blocks tumor necrosis factor, or TNF, and which competes with Johnson & Johnson’s older blockbuster medication Remicademore

Sanofi hits back on “poor quality” Lantus studies.

Roche leaving PhRMA – Hoffman La Roche is severing its ties to Big Pharma. The venerable drug maker this week plans to drop its membership in the Pharmaceutical Research and Manufacturers Association. PhRMA, as it is known informally, is the leading trade group for the U.S. pharmaceutical industrymore

PLUS – on the far reaches of the cancer treatment galaxy – Australian scientists have developed a “trojan horse” therapy to combat cancer, using a bacterially-derived nano cell to penetrate and disarm the cancer cell before a second nano cell kills it with chemotherapy drugsmore

AND – the doctor will text you now.

——

Subscribe to the Impactiviti blog via e-mail

Subscribe to the Impactiviti blog via RSS

Connect with Steve Woodruff

Read Full Post »

I think it’s going to be more than 3 today…!

Does Lantus (Sanofi drug for diabetes) increase cancer risk?

Takeda‘s alogliptin (new diabetes treatment) – FDA says, more info please.

European Medicines Agency approves a variety pack of new drugs and expanded indications. Here’s the rundown.

Drug companies increasingly using Medical Science liaisons. In my industry crystal ball, I think MSL-type folks will increasingly replace pharma sales reps. More from the original WSJ article here.

Newest version of Elan rumors – Novartis perhaps buying the MS part of the portfolio? Could make sense, given Novartis’ recent entry into that therapeutic area.

Roche: bye-bye Accutane – Roche is pulling its Accutane acne medicine from the U.S. market after juries awarded at least $33 million in damages to users who blamed the drug for bowel disease. Roche notified the U.S. Food and Drug Administration today that it was withdrawing Accutane after a “reevaluation” of its product lines showed it faced serious challenges from generic competitors, company officials said in a statement...more

——

Subscribe to the Impactiviti blog via e-mail

Subscribe to the Impactiviti blog via RSS

Connect with Steve Woodruff

Read Full Post »

« Newer Posts - Older Posts »